Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel Precision Medicines for Chronic Kidney Diseases - Seite 2

The collaboration also leverages Evotec’s proprietary PanOmics platform, which combines enhanced throughput proteomics, high throughput transcriptomics and cell imaging with PanHunter, Evotec’s unique data analysis platform.

“We are glad to enter into a discovery and development partnership with Chinook Therapeutics, a company specializing in overcoming kidney diseases. CKD is a collective term for a variety of diseases that cause a gradual loss of kidney function. The diversity in the underlying causes makes this area especially favorable for data-driven and systematically personalized approaches,” said Cord Dohrmann, Ph.D., Chief Scientific Officer of Evotec. “By leveraging our complementary platforms, Evotec and Chinook have the best possible starting position to tackle particular rare forms of CKD with the goal to develop disease-modifying therapeutics for underserved patient populations.”

Under the terms of the agreement, Chinook and Evotec will share drug discovery and preclinical development responsibilities. Chinook will be responsible for clinical development and commercialization of product candidates developed under the collaboration. Evotec will receive an undisclosed upfront payment, research funding, progress-dependent milestone payments and tiered royalties on net sales for targets identified through the collaboration.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, an investigational phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. BION-1301, an investigational anti-APRIL monoclonal antibody, is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an investigational oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.